Skip to content

Screening for Amyloidosis Before Aortic Valve Elective Replacement

Screening for Amyloidosis Before Aortic Valve Elective Replacement (SAVER)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04869631
Acronym
SAVER
Enrollment
1000
Registered
2021-05-03
Start date
2021-02-01
Completion date
2028-03-31
Last updated
2025-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyloidosis, Aortic Valve Stenosis

Keywords

Cardiac Amyloidosis, Transthyretin Amyloidosis, ATTR, Aortic Stenosis, Screening

Brief summary

Previous studies detected that up to 15% of patients undergoing aortic valve replacement (AVR) for degenerative aortic stenosis have concomitant transthyretin amyloidosis (ATTR) cardiomyopathy (Castano, 2017). The aim of this study is to investigate the effectivity and practicability of a systematic ATTR-Screening in patients undergoing planned AVR. Moreover, we plan to develop a screening algorithm to detect ATTR in aortic stenosis (AS).

Detailed description

Untreated cardiac amyloidosis is accompanied with an impaired prognosis. Amyloidosis is often associated with ventricular hypertrophy which leads to severe heart failure and occurs frequently in conjunction with bradycardic or tachycardic malignant arrhythmia. Patients with degenerative aortic valve stenosis suffer more frequently from cardiac ATTR. However, it remains unclear whether the development of aortic stenosis is promoted by ATTR. Due to very similar symptoms (shortness of breath during physical exertion, reduced walking distance) diagnosis of aortic valve stenosis is more often diagnosed in a typical cohort of patients aged between 70-80 years but, in contrast, leads to underdiagnosis of patients with additional cardiac amyloidosis. Six to fifteen percent of patients with aortic valve replacement due to degenerative aortic valve stenosis exhibit a cardiac amyloidosis. Since cardiac amyloidosis without therapeutic intervention is associated with significantly reduced life expectancy, it can be assumed that these patients will not benefit to the same extent from the AVR alone as patients without ATTR. New therapeutic approaches for patients exhibiting ATTR lead to a reduction of mortality and hospitalizations. The primary aim of this study is to establish a simple ATTR screening tool in patients with planned AVR in the clinical routine and, furthermore, to compare the clinical course following AVR between patients with and without ATTR.

Interventions

OTHERThe outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.

We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.

Sponsors

Deutsches Herzzentrum Berlin, Klinik für Innere Medizin - Kardiologie
CollaboratorUNKNOWN
Klinik für Neurologie mit Experimenteller Neurologie, Charité - Universitätsmedizin Berlin
CollaboratorUNKNOWN
Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* age ≥40 years * written informed consent from the patient or of his/her legal guardian * hospitalization for AVR due to degenerative aortic valve stenosis

Exclusion criteria

* hemodynamically unstable patient * severe co-morbidities with an estimated life expectancy of \<1 year

Design outcomes

Primary

MeasureTime frame
Number/ proportion of ATTR cases identified by systematic screeningEnrolment period: 18 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026